Creutzig Ursula, Dworzak Michael N, Bochennek Konrad, Faber Jörg, Flotho Christian, Graf Norbert, Kontny Udo, Rossig Claudia, Schmid Irene, von Stackelberg Arend, Mueller Jans-Enno, von Neuhoff Christine, Reinhardt Dirk, von Neuhoff Nils
Department of Pediatric Hematology/Oncology, Hannover Medical School, Children's Hospital, Hannover, Germany.
Department of Pediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23.
Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.
最近，针对成人急性早幼粒细胞白血病（APL）的研究表明，对于接受全反式维甲酸（ATRA）和三氧化二砷（ATO）治疗的低危患者，治愈率很高，同时与ATRA和化疗的标准治疗相比，毒性显著降低。在此，我们报告11例接受ATRA和ATO治疗的低危儿童APL患者的首次治疗经验。所有患者均处于分子缓解状态。所有患者均患有白细胞增多症。两名患者出现可逆性严重副作用。一名患者双侧股骨出现骨坏死、癫痫发作以及后部可逆性脑病综合征，另一名患者患有外展神经麻痹。
